Sodium Butyrate — The Epigenetic Gut Metabolite
Sodium butyrate is a short-chain fatty acid naturally produced by gut microbial fermentation of dietary fibre. It serves as a primary energy source for colonocytes and acts systemically as a histone deacetylase (HDAC) inhibitor, promoting epigenetic regulation, reducing inflammation, and supporting gut barrier integrity.
Mechanism of Action
As a potent inhibitor of class I and IIa histone deacetylases (HDACs), sodium butyrate promotes histone acetylation, leading to the transcriptional activation of genes involved in cell differentiation, apoptosis, and anti-inflammatory pathways. It suppresses nuclear factor-kappa B (NF-κB) activation, thereby reducing the production of pro-inflammatory cytokines. In the gut, it binds to G-protein-coupled receptors (GPR41 and GPR43) to modulate immune responses and enhance tight junction protein expression, reinforcing the intestinal barrier. Systemically, its epigenetic effects may enhance neuroplasticity and metabolic homeostasis.
Human Trial Evidence
Human trials have primarily focused on its use in inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and metabolic disorders. Clinical studies demonstrate that oral sodium butyrate supplementation can reduce abdominal pain in IBS and improve mucosal inflammation in ulcerative colitis. However, large-scale, long-term human trials specifically evaluating its effects on systemic aging and longevity are currently lacking.
Dosing Protocol
In clinical studies for gut health, oral doses typically range from 150 mg to 600 mg per day, often administered in divided doses. Enteric-coated or microencapsulated formulations are preferred to ensure delivery to the lower gastrointestinal tract and prevent premature absorption in the stomach. It is generally taken with meals.
Safety & Contraindications
Sodium butyrate is generally well-tolerated with a high safety profile. Mild gastrointestinal side effects, such as bloating, flatulence, or altered bowel habits, may occur at higher doses. It has a distinct, pungent odour that some find unpleasant, though encapsulated forms mitigate this issue. There are no major known drug interactions, but caution is advised in individuals with severe hepatic impairment.